Kymera Therapeutics
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
Corporate information
- Company entity
- Kymera Therapeutics, Inc.
- Headquarters / principal office
- Watertown, MASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- Incorporated in 2015 / business launched in 2016 ↗
- Ownership / capital status
- Publicly tradedPublicly traded ↗
- Official corporate reference
- https://www.kymeratx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.